Company news
-
ImmuneOnco sets up wholly-owned subsidiary—ImmuneOnco BioPharm (Shanghai) Co., Ltd.On September 28, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") wholly-owned subsidiary-ImmuneOnco BioPharm (Shanghai) Co., Ltd. was established in Zhangjiang Science City (hereinafter ......2021-09-28
-
ImmuneOnco:Clinical Research Application for IMM27M was accepted by the National Medical Products Administration (NMPA)On September 1, 2021, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that clinical research application for newly developed IMM27M, an ADCC-enhanced CTLA-4 antibody, has been officially accepted by N......2021-09-06
-
ImmuneOnco Received NMPA Authorization to Proceed with 3 Phase Ib/IIa Clinical Trials of IMM01 Combined with Azacytitin, Rituximab and InetetamabAugust 25, 2021, Shanghai, China ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. ( hereinafter referred to as "ImmuneOnco") announced that 3 phase Ib/IIa trials of company’s lead drug candidate, IMM01, Fc fusion protein targeting CD47,the first in China,......2021-08-26
-
ImmuneOnco received FDA approval of IMM2902 as an Investigational New Drug (IND) in the United StatesAugust 21, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the U.S. Food and Drug Administration (FDA) has granted permission to IMM2902, a bi-specific antibody-receptor recom......2021-08-24
-
ImmuneOnco Succesfully Finished First-in-Human Dosing of Its Bi-Specific Fusion Protein IMM2510August 18, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that first-in-human (FIH) dosing of IMM2510, the second product of bi-specific antibodies in clinical stage, has been......2021-08-19